Sonoma Pharmaceuticals announced a nationwide retail expansion as it introduced its advanced burn relief hydrogel across major U.S. outlets. The company confirmed that it will distribute the burn relief hydrogel through CVS and Walmart stores, thereby strengthening its consumer healthcare presence. The newly launched burn relief hydrogel uses hypochlorous acid technology, which clinicians widely recognize for its antimicrobial and skin-soothing properties. Moreover, the burn relief hydrogel targets minor burns and skin irritations, while it also supports the body’s natural healing response effectively.
Sonoma Pharmaceuticals emphasized that the burn relief hydrogel offers a gentle and non-irritating formulation for everyday consumer use. Additionally, the burn relief hydrogel addresses seasonal concerns such as sunburn, which continues to drive demand for accessible over-the-counter solutions. The company stated that this burn-relief hydrogel marks its first large-scale consumer-focused burn care product in the United States market. Previously, Sonoma Pharmaceuticals established a strong clinical presence, as healthcare providers used its hypochlorous acid solutions in advanced wound care settings.
However, the burn relief hydrogel launch reflects a broader strategic shift toward retail expansion and consumer accessibility across major distribution channels. Therefore, Sonoma Pharmaceuticals partnered with a U.S.-based distributor to ensure that the burn relief hydrogel reaches nationwide store shelves efficiently.
Chief Executive Officer Amy Trombly highlighted that the burn relief hydrogel builds on the company’s earlier success in consumer product innovation. She noted that increasing awareness of hypochlorous acid has encouraged consumers to adopt safer and clinically backed skincare solutions, including burn relief hydrogel products. Furthermore, the burn relief hydrogel launch follows Sonoma’s 2025 rollout of a diaper rash hydrogel in mass retail markets. This earlier initiative demonstrated the company’s ability to scale clinically proven technologies into consumer-friendly formats, which now supports the burn relief hydrogel expansion.
Industry analysts observed that the burn relief hydrogel introduction aligns with growing demand for over-the-counter dermatological treatments. In addition, consumers increasingly prefer products that combine safety, effectiveness, and ease of application, which strengthens the market position of burn relief hydrogel solutions. The burn relief hydrogel also complements Sonoma’s broader portfolio of hypochlorous acid-based products designed for medical, veterinary, and personal care applications. Consequently, the company continues to expand its global footprint, as it supports distribution partners across more than 50 countries.
Meanwhile, Sonoma Pharmaceuticals maintains manufacturing operations in Mexico and corporate headquarters in Boulder, Colorado, to support production and innovation. These capabilities enable the company to scale burn relief hydrogel manufacturing while maintaining regulatory compliance and quality standards. Investors responded positively to the burn relief hydrogel announcement, as the company continues to diversify its consumer product offerings. Although the company remains in a growth phase, the burn relief hydrogel launch signals potential revenue opportunities in the expanding over-the-counter healthcare segment.
Looking ahead, Sonoma Pharmaceuticals plans to leverage strategic partnerships and innovation pipelines to expand its retail portfolio further. As a result, the burn relief hydrogel may serve as a cornerstone product that drives brand recognition and consumer trust in the coming years. In conclusion, the nationwide rollout of burn relief hydrogel represents a significant milestone for Sonoma Pharmaceuticals as it strengthens its consumer healthcare strategy. With increasing demand for effective and gentle treatments, the burn relief hydrogel positions the company to compete in a rapidly evolving retail healthcare market.
